Prevalence and Economic Burden of Respiratory Diseases in Central Asia and Russia: A Systematic Review

International Journal of Environmental Research and Public Health

Niels H. Chavannes¹  Job F. M.van Boven²  Berik Emilov³  Talant Sooronbaev³  Aizhamal Tabyshova³  Maarten J. Postma⁴ 

[1] Department of Public Health and Primary Care, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands;Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands;Pulmonology Department, National Center of Cardiology and Internal Medicine named after M.M. Mirrakhimov, Bishkek 720040, Kyrgyzstan;Unit of Global Health, Department of Health Sciences, University Medical Center Groningen, University of Groningen, 9700 RB Groningen, The Netherlands;

关键词: prevalence;    economic burden;    chronic respiratory diseases;    Central Asia;    Russia;   

DOI  :  10.3390/ijerph17207483

来源: DOAJ

【 摘 要 】

Prevalence data of respiratory diseases (RDs) in Central Asia (CA) and Russia are contrasting. To inform future research needs and assist government and clinical policy on RDs, an up-to-date overview is required. We aimed to review the prevalence and economic burden of RDs in CA and Russia. PubMed and EMBASE databases were searched for studies that reported prevalence and/or economic burden of RDs (asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis, interstitial lung diseases (ILD), lung cancer, pulmonary hypertension, and tuberculosis (TB)) in CA (Kyrgyzstan, Uzbekistan, Tajikistan, Kazakhstan, and Turkmenistan) and Russia. A total of 25 articles (RD prevalence: 18; economics: 7) were included. The majority (n = 12), mostly from Russia, reported on TB. TB prevalence declined over the last 20 years, to less than 100 per 100,000 across Russia and CA, yet in those, multidrug-resistant tuberculosis (MDR-TB) was alarming high (newly treated: 19–26%, previously treated: 60–70%). COPD, asthma (2–15%) and ILD (0.006%) prevalence was only reported for Russia and Kazakhstan. No studies on cystic fibrosis, lung cancer and pulmonary hypertension were found. TB costs varied between US$400 (Tajikistan) and US$900 (Russia) for drug-susceptible TB to ≥US$10,000 for MDR-TB (Russia). Non-TB data were scarce and inconsistent. Especially in CA, more research into the prevalence and burden of RDs is needed.

【 授权许可】

Unknown